Alan Musso
About Alan Musso
Independent director since October 2023; age 63. Career CFO across public and private biopharma; designated as the Board’s audit committee financial expert. Education: B.S. in Accounting (Saint Mary’s College of California) and Master’s degree from Thunderbird School of Global Management .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Fulcrum Therapeutics (NASDAQ: FULC) | Chief Financial Officer | Aug 2023–present | Public-company CFO; finance oversight |
| ReViral Ltd (acquired by Pfizer) | Chief Financial Officer | Oct 2019–Sep 2022 | Led finance through sale to Pfizer |
| Peloton Therapeutics (acquired by Merck) | Chief Financial Officer & Treasurer | Sep 2018–Sep 2019 | IPO readiness; sale to Merck in Jul 2019 |
| Bellicum Pharmaceuticals (NASDAQ: BLCM) | Chief Financial Officer & Treasurer | Nov 2014–Aug 2018 | Public-company finance leadership |
| Targacept, Inc. | Various finance roles | Feb 2002–Nov 2014 | Biopharma finance |
| Pfizer | Senior Internal Auditor | Early career | Audit foundation |
| KPMG | Certified Public Accountant | Early career | Public accounting experience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Lung Therapeutics, Inc. | Director | Apr 2022–Oct 2023 | Served until RNTX’s Lung Acquisition in Oct 2023 |
| Other current public company directorships | — | — | None disclosed beyond RNTX |
Board Governance
- Committees: Audit Committee (Chair), Compensation Committee (Member); not on Nominating & Corporate Governance .
- Independence: Board determined Mr. Musso is independent under Nasdaq and SEC rules; designated “audit committee financial expert” .
- Attendance: Board met 7 times in 2024; each incumbent director attended at least 75% of Board and applicable committee meetings. Audit Committee met 4 times; Compensation Committee met 2 times; Nominating & Corporate Governance met 1 time .
- Executive sessions: Independent directors meet at least twice per year .
Fixed Compensation
| Component | 2024 Amount | Notes |
|---|---|---|
| Director cash fees earned | $67,500 | Cash retainer plus committee fees per 2024 program |
| 2024 program board retainer | $35,000 | Pre-Nov 2024 structure |
| 2024 program committee fees | Audit: Chair $22,500; Member $15,000; Compensation: Chair $15,000; Member $10,000; Nominating: Chair $11,250; Member $7,500 | Pre-Nov 2024 structure |
| Revised program board retainer (adopted Nov 2024) | $40,000 | Effective with revision |
| Revised program committee fees | Same committee rates as 2024 program | Effective with revision |
Performance Compensation
| Award Type | Grant Date | Shares | Exercise Price | Vesting | Expiration |
|---|---|---|---|---|---|
| Stock option (annual director grant under revised program) | Dec 2, 2024 | 35,000 | $2.85 | Vests in full on Dec 2, 2025 | Dec 1, 2034 |
| Stock option (annual director grant) | Jul 23, 2025 | 17,500 | $1.55 | Vests in full on earlier of Jul 23, 2026 or 2026 Annual Meeting | Jul 22, 2035 |
- As of Dec 31, 2024, Mr. Musso held 60,239 options in aggregate (including assumed options from Lung), consistent with director holdings disclosure .
- No director performance metrics disclosed; director equity awards are time-based option grants under the non-employee director program .
Other Directorships & Interlocks
| Company | Overlap/Interlock | Potential Conflict |
|---|---|---|
| Fulcrum Therapeutics (CFO role) | None disclosed with RNTX customers/suppliers | Board determined independence; no related-party transactions with Fulcrum disclosed |
| Bios Partners-related financings | Audit Committee oversees related person transactions; chair role held by Musso | Transactions with Bios Partners disclosed; no personal interest by Musso disclosed |
Expertise & Qualifications
- Deep finance leadership in biopharma; CPA background; internal audit experience at Pfizer; recognized by Board as audit committee financial expert .
- Skills aligned with Audit and Compensation oversight, including capital markets, M&A transaction experience (e.g., Peloton sale to Merck; ReViral sale to Pfizer) .
Equity Ownership
| Measure | As of | Amount | Notes |
|---|---|---|---|
| Total beneficial ownership | Mar 31, 2025 | 19,107 shares (via options exercisable within 60 days) | Represents <1% of outstanding shares |
| Shares owned directly | Mar 31, 2025 | 0 disclosed | Beneficial ownership via options only |
| Options outstanding (director group context) | Dec 31, 2024 | Musso: 60,239 options | Director holdings table |
| Hedging/Pledging | Policy status | Prohibited for directors (short sales, puts/calls, hedging, margin/pledges) | Company insider trading policy |
| Ownership guidelines | — | Not disclosed for directors | No formal director ownership guidelines disclosed |
Insider Trades
| Filing | Date | Security | Shares | Price/Strike | Vesting/Notes |
|---|---|---|---|---|---|
| Form 4 | Dec 6, 2024 | Stock option | 35,000 | $2.85 | Vests in full on Dec 2, 2025; 10-year term |
| Form 4 | Jul 23, 2025 | Stock option | 17,500 | $1.55 | Vests earlier of Jul 23, 2026 or 2026 Annual Meeting; expires Jul 22, 2035 |
Governance Assessment
-
Strengths
- Independent director with public-company CFO pedigree; designated audit committee financial expert; chairs Audit Committee and serves on Compensation Committee .
- Clear committee charters and robust risk oversight; anti-hedging policy and Nasdaq-compliant clawback policy in place; related-party transaction review under Audit Committee purview .
- Board and committee engagement: ≥75% attendance for incumbents; defined meeting cadence across committees .
-
Watch items / potential investor confidence signals
- Pay structure changes: Board increased director cash retainer and significantly enlarged equity grant sizes in late 2024 (from 2,725 options to 35,000 options), potentially elevating director pay levels at a smaller reporting company .
- Ownership alignment: Beneficial ownership disclosed primarily via options (19,107 exercisable within 60 days; <1%); no direct share ownership disclosed, suggesting limited “skin-in-the-game” beyond option exposure .
- External demands: Concurrent CFO role at another public biotech (Fulcrum) could pose time-allocation considerations; Board nevertheless affirmed independence and committee suitability .
-
No RED FLAGS disclosed specific to Musso
- No related-party transactions tied to Musso; no pledging/hedging permitted; no legal proceedings or SEC investigations disclosed in proxy; Audit Committee chaired by Musso responsible for related-party oversight .